Tech

Stocks Tumble After Flurry of Bank Earnings, Inflation and Retail Sales Data; Gold, Silver Set Fresh Record Highs

January 14, 2026 12:52 PM EST

Chinese Antitrust Probe Sends This Travel Stock Plummeting—What Investors Need to Know

FROM 12 minutes ago

An investigation by Chinese authorities sent a travel stock tumbling Wednesday.

U.S.-listed shares of Trip.com (TCOM) were down nearly 17% in recent trading after China’s State Administration for Market Regulation said it’s investigating the company over potential monopolistic behavior as a dominant travel player in the region.

Trip.com said in a statement that it will cooperate with the investigation and is operating its business as usual.

Cheng Xin / Getty Images


Chinese regulators have been paying closer attention to the operations of large tech companies in recent years. Last year, regulators in the country found that Nvidia (NVDA) had violated antitrust law with a previous acquisition after announcing an investigation in December 2024.

Last week, Chinese authorities said they would look into Meta Platforms’ (META) acquisition of AI startup Manus announced last month, to ensure it is compliant with Chinese export laws.

With Wednesday’s losses, Trip.com shares are down 14% for the year so far after climbing about 5% in 2025.

Aaron McDade

January 14, 2026 12:19 PM EST

Bank of America CEO Moynihan Predicts Economic Growth Despite ‘Risks’ in 2026

FROM 45 minutes ago

A second big-bank CEO in as many days is sharing upbeat sentiment about the U.S. economy.

Bank of America’s (BAC) Brian Moynihan on Wednesday said while reporting the bank’s latest quarterly financial results that he expects “further economic growth in the year ahead.”

Bank of America CEO Brian Moynihan.

Chris J. Ratcliffe / Bloomberg via Getty Images


The statement followed comments yesterday from JPMorgan Chase (JPM) chief Jamie Dimon, who referenced a “resilient” economy but also highlighted a set of “hazards,” including inflation and geopolitical risks, that he thought markets were underappreciating.

“With consumers and businesses proving resilient, as well as the regulatory environment and tax and trade policies coming into sharper focus, we expect further economic growth in the year ahead,” Moynihan said in a statement. “While any number of risks continue, we are bullish on the U.S. economy in 2026.”

Read the full article here.

David Marino-Nachison

January 14, 2026 11:41 AM EST

Energy Sector Outperforms on Down Day for S&P 500

FROM 1 hr 23 min ago

The S&P 500 is having a rough day thus far. Don’t blame energy stocks.

The S&P 500 Energy Sector was up nearly 2.4%, by far the biggest gainer of the 11 sectors tracked by the benchmark index.

Leading performers in the sector include APA (APA), up about 4.5%; Devon Energy (DVN), up 3.5%; and ConocoPhillips (COP), up 3.5%.

Interestingly, more than half of the sectors (6) are in positive territory Wednesday, but the index overall is down 0.8%.

TradingView


January 14, 2026 10:06 AM EST

Strategy Stock Surges Further Along With Bitcoin

FROM 2 hr 58 min ago

Bitcoin is rising again. So are shares of Strategy.

Strategy (MSTR) was the top-performing stock in the Nasdaq early Wednesday, with shares up more than 6%.

Shares of the Bitcoin-treasury firm had surged 6.6% Tuesday as the price of the largest cryptocurrency jumped. Bitcoin recently was trading around $95,800, up from the day’s low of roughly $94,100.

Strategy shares were trading around $185, well off their all-time high of $457.22 set last July 16, when bitcoin was trading around $120,000.

TradingView


January 14, 2026 09:48 AM EST

AI Could Spell Trouble for Software. These Experts Say to Avoid One Stock In Particular

FROM 3 hr 16 min ago

Software was once the hottest industry on Wall Street. Not so in the AI era.

S&P 500 software stocks lagged the broader index for the second consecutive year in 2025 as companies making the “picks and shovels” of the AI buildout—like semiconductors and memory devices—led the stock market higher. And analysts expect the challenges weighing on software stocks, especially application developers, to persist in 2026.

One example: Oppenheimer on Tuesday downgraded Adobe (ADBE) stock to “Perform” from “Outperform” and withdrew its price target entirely, citing threats from AI that apply to varying degrees across the application software industry. The news pulled Adobe, shares of which have lost more than a fifth of their value over the past 12 months, down more than 5% yesterday, and they ticked a further 0.5% lower soon after the opening bell Wednesday.

Software stocks lagged the market for a second straight year in 2025.

ANGELA WEISS / AFP via Getty Images


One of the primary issues Adobe faces, according to Oppenheimer, is the perception that AI is weakening its competitive position. Gen AI “is increasing the velocity of content creation while lowering price and subscriber growth,” wrote analysts led by Brian Schwartz. The company faces new competition from LLM providers like OpenAI and advertising platforms like Meta, which have introduced creative tools that allow people other options for doing what previously required an Adobe license and specialized knowledge.

Read the full article here.

Colin Laidley

January 14, 2026 08:12 AM EST

TG Therapeutics Stock Surges on Lifted Sales Outlook Following Success of Multiple Sclerosis Drug

FROM 4 hr 52 min ago

TG Therapeutics (TGTX) shares popped 10% in premarket trading Wednesday, a day after the biopharmaceutical firm lifted its full-year revenue projections in a presentation at the 44th Annual J.P Morgan Healthcare Conference.

The New York-based firm now sees fiscal 2025 revenue of $616 million, up from the prior projection of $600 million, and sales of multiple sclerosis treatment Briumvi of $594 million, up from the previous guidance of $585 million. Both figures were above Visible Alpha consensus forecasts.

“Briumvi continued to deliver strong commercial performance in 2025, reinforcing our confidence in the multi-billion dollar opportunity for Briumvi,” CEO Michael Weiss said.

The company also sees 2026 revenue of about $875 million to $900 million, including Briumvi U.S. net product revenue of around $825 million to $850 million. The Briumvi projection was well above the Visible Alpha estimate, while the total revenue figure was in line with expectations.

TG Therapeutics shares entered the day down 6% over the past year.

TradingView


January 14, 2026 06:51 AM EST

Stock Futures Fall Ahead of Flurry of Bank Earnings, PPI Inflation Data

FROM 6 hr 13 min ago

Futures contracts associated with the Dow Jones Industrial Average pointed 0.3% lower.

TradingView


S&P 500 futures were down 0.4%.

TradingView


Nasdaq 100 futures declined 0.6%.

TradingView


Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button